Mostrar el registro sencillo del ítem

dc.contributor.author
Pérez Montilla, Carlos Alberto  
dc.contributor.author
Schaiquevich, Paula Susana  
dc.contributor.author
Caceres Guido, Paulo Arturo  
dc.contributor.author
Caraballo, Roberto Horacio  
dc.contributor.author
Reyes Valenzuela, Gabriela  
dc.contributor.author
Cruz, Cintia V.  
dc.contributor.author
García Bournissen, Facundo  
dc.date.available
2022-07-22T18:18:03Z  
dc.date.issued
2021-10  
dc.identifier.citation
Pérez Montilla, Carlos Alberto; Schaiquevich, Paula Susana; Caceres Guido, Paulo Arturo; Caraballo, Roberto Horacio; Reyes Valenzuela, Gabriela; et al.; An Ultrafast Ultrahigh-Performance Liquid Chromatography Coupled With Tandem Mass Spectrometry Method for Cannabidiol Monitoring in Pediatric Refractory Epilepsy; Lippincott Williams; Therapeutic Drug Monitoring; 43; 5; 10-2021; 1-26  
dc.identifier.issn
0163-4356  
dc.identifier.uri
http://hdl.handle.net/11336/162942  
dc.description.abstract
Background: Cannabidiol (CBD) is a nonpsychoactive natural product that has been increasingly used as a promising new drug for the management of neurological conditions such as refractory epilepsy. Development of rapid and sensitive methods to quantitate CBD is essential to evaluate its pharmacokinetics in humans, particularly in children. The objective of this work was to develop and validate an ultrafast ultrahigh-performance liquid chromatography coupled with tandem mass spectrometry (UHPLC-MS/MS) method for CBD quantitation that is capable of detecting major CBD and tetrahydrocannabinol (THC) metabolites in the plasma of pediatric refractory epilepsy patients.Methods: Eight-point CBD calibration curves were prepared using 60 µL of plasma from healthy volunteers. Samples were analyzed in a Shimadzu Nexera X2 UHPLC system, which was coupled to a Sciex QTRAP 6500 mass spectrometer. Chromatography was optimized in acetonitrile (ACN)/water with a 70%-90% gradient of ACN in 2 minutes. Multiple reaction monitoring transitions of major CBD and THC metabolites were optimized in patient plasma.Results: The optimized UHPLC-MS/MS method was validated for the linear range (1-300 ng/mL) of CBD (r2 = 0.996). The limit of quantification and limit of detection were 0.26 and 0.86 ng/mL, respectively. Accuracy and precision met the acceptable validation limits. CBD recovery and matrix effects were 83.9 ± 13.9% and 117.4 ± 4.5%, respectively. The method was successfully applied to quantify CBD and detect the major CBD and THC metabolites in clinical samples. 7-COOH-CBD was the most intensely detected metabolite followed by glucuronide conjugates.Conclusions: A simple and sensitive method for rapidly monitoring CBD and identifying relevant metabolites was developed. Its applicability in samples from children treated for epilepsy was demonstrated, making it an excellent alternative for performing pharmacokinetic studies.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Lippincott Williams  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
Cannabidiol  
dc.subject
HPLC  
dc.subject
Refractory epilepsia  
dc.subject
Monitoring  
dc.subject.classification
Neurociencias  
dc.subject.classification
Medicina Básica  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
An Ultrafast Ultrahigh-Performance Liquid Chromatography Coupled With Tandem Mass Spectrometry Method for Cannabidiol Monitoring in Pediatric Refractory Epilepsy  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2022-07-20T15:13:08Z  
dc.journal.volume
43  
dc.journal.number
5  
dc.journal.pagination
1-26  
dc.journal.pais
Estados Unidos  
dc.journal.ciudad
Philadelphia  
dc.description.fil
Fil: Pérez Montilla, Carlos Alberto. Gobierno de la Ciudad de Buenos Aires. Instituto Multidisciplinario de Investigaciones en Patologías Pediátricas. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto Multidisciplinario de Investigaciones en Patologías Pediátricas; Argentina  
dc.description.fil
Fil: Schaiquevich, Paula Susana. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; Argentina  
dc.description.fil
Fil: Caceres Guido, Paulo Arturo. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; Argentina  
dc.description.fil
Fil: Caraballo, Roberto Horacio. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; Argentina  
dc.description.fil
Fil: Reyes Valenzuela, Gabriela. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; Argentina  
dc.description.fil
Fil: Cruz, Cintia V.. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Farmacología; Argentina  
dc.description.fil
Fil: García Bournissen, Facundo. Gobierno de la Ciudad de Buenos Aires. Instituto Multidisciplinario de Investigaciones en Patologías Pediátricas. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto Multidisciplinario de Investigaciones en Patologías Pediátricas; Argentina. Western University; Canadá  
dc.journal.title
Therapeutic Drug Monitoring  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1097/FTD.0000000000000846  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://journals.lww.com/drug-monitoring/Abstract/2021/10000/An_Ultrafast_Ultrahigh_Performance_Liquid.18.aspx